Author

K. Berger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:fluorescence / live-cell microscopy· 1 Organism:human· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

A. A. Mangaonkar· 1 shared A. Buradkar· 1 shared A. El kaoutari· 1 shared A. Mathison· 1 shared A. Vedder· 1 shared A. Yurchenko· 1 shared B. Alver· 1 shared C. Johnson· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Mangaonkar

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

EZH2 deletion does not impact acinar cell regeneration but restricts progression to pancreatic cancer in mice

E. Jaune-Pons, X. Wang, F. Mousavi, A. El kaoutari, K. Berger, C. Johnson, M. Martin, S. Aggarwal, S. Brar, K. Muhammad, P. Shooshtari, A. Mathison, N. Dusetti, R. Urrutia, G. Lomberk, C. L. Pin

This study shows EZH2 deletion in adult acinar cells does not block regeneration but limits PDAC progression by altering the tumor microenvironment and differentiation.

bioRxiv · Sep 25, 2023 · PreprintCancer Biology

Topography and motion of the acid-sensing ion channel intracellular domains

T. Couch, K. Berger, D. L. Kneisley, T. W. McCullock, P. J. Kammermeier, D. M. MacLean

This study uses FRET to map the topography and motion of ASIC1 intracellular domains, revealing structural features and conformational changes under acidification.

bioRxiv · Feb 23, 2021Physiology

RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis

R. M. Carr, D. Vorobyev, T. Lasho, D. L. Marks, E. J. Tolosa, A. Vedder, L. Almada, A. Yurchenko, I. Padioleau, B. Alver, G. Coltro, M. Binder, S. L. Safgren, I. Horn, X. You, , M. M. Patnaik

This study identifies RAS mutations as drivers of proliferative CMML through a novel KMT2A-PLK1 axis, showing PLK1 inhibition can improve disease outcomes in patient-derived xenografts.

bioRxiv · Dec 23, 2019 · PreprintCancer Biology